3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Hyperphagia
9
Malnutrition
4
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Hematologic Neoplasms
2
Postoperative Complications
1
Nutritional Support
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Hematopoietic and Lymphatic System Neoplasm
1
Head and Neck Neoplasms
1
Glucocorticoid Receptor Deficiency
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Deglutition Disorders
1
Interventions
Capecitabine
6
Irinotecan
5
Fluorouracil
5
Cisplatin
5
Oxaliplatin
4
Leucovorin
4
Gemcitabine
4
apatinib
3
Sorafenib
3
Bevacizumab
3
tislelizumab
2
pembrolizumab
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cyclophosphamide
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
lutetium Lu 177 dotatate
1
huachansu
1
halofantrine
1
guadecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Digestive System Neoplasms
×
Parenteral Nutrition
×
Clear all
NCT03115957
2020-09-29
PNASIT
Jinling Hospital, China
Phase NA
Completed
230 enrolled